Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM-H2 in Advanced HER2-Positive Cancer
NCT04467515Phase 2Terminated
- Sponsor
- Precirix
- Start
- Sep 2021
- Primary completion
- Dec 2023
- Modality
- Nanobodies (VHH)
- Countries
- 2
01
Overview
A Phase 2 trial of CAM-H2 in HER2-positive breast cancer, gastric cancer (GC), gastroesophageal junction cancer, sponsored by Precirix. Started Sep 2021; status: terminated.
02
Drugs
CAM-H2
03
Conditions
HER2-positive breast cancergastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04467515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04467515.